EGFR

News

Blueprint inks deal to buy lung cancer biotech Lengo

Targeted cancer drug specialist Blueprint Medicines has agreed to pay $250 million upfront to acquire Lengo Therapeutics and its lead drug for lung cancer, a rival to already-approved thera

News

Takeda gets a win for its Wave1 pipeline, as Exkivity nabs F...

Takeda has had a run of bad luck with its Wave1 pipeline of new drug candidates of late, but can now celebrate a vestry after getting FDA approval for first-in-class lung cancer therapy Exk

Events

Partner Content

Non-Small Cell Lung Cancer Drug Development Summit

Largest solid tumor indication: The definitive forum

Blueprint inks deal to buy lung cancer biotech Lengo

Takeda gets a win for its Wave1 pipeline, as Exkivity nabs F...

Non-Small Cell Lung Cancer Drug Development Summit

TransThera's resistant biliary cancer drug cleared in China

Discover a new era of healthcare panel engagement: Grounded ...

Editor's Picks